Urtidin F.C Tablet

Adjuvant treatment for Irritable Bladder

Adjuvant treatment for the voiding symptoms (sensation of poor bladder emptying, dribbling, hesitancy) in stage I and II of Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia (BPH) is one of the most prevalent urologic disorders in men, affecting 90% of men over 65, which manifests itself as obstructive and irritative symptoms.

Use of stinging nettle root for prostate and irritable bladder complaints has been approved by Comission E. Products made of stinging nettle root have been used to treat the voiding symptoms in stage I and II of BPH and alleviate its symptoms without causing a reduction in the size of the prostate. Based on the views of this commission, stinging nettle root reduces residual urine and increases urine flow.

In numerous pharmacological studies, the following mechanisms of action have been proposed for stinging nettle root extract:

1- The active ingredients in the extract of stinging nettle root, like lignans, bind to Sex Hormone Binding Globulin (SHBG) and prevent it from binding to the prostate.

2- Steroidal compounds present in raw extract of stinging nettle root accelerate the movement of macrophages to their target and aids the anti-inflammatory effects of the drug. Furthermore, steroids inhibit the function of Na+K+ATPase enzyme and therefore inhibit the metabolism and growth of prostate cells.

3- The extract of stinging nettle root inhibits 5α-reductase and aromatase.

4- The extract of stinging nettle root inhibits cellular proliferation in BPH.

In a placebo-controlled clinical trial including 79 patients suffering BHP, stinging nettle root extract (600 mg per day, 5:1 extract for 6-8 weeks) was superior to the placebo in all measured parameters (urine flow and volume, residual urine). In another similar clinical trial, 50 patients with stage I and II BPH, who were administered stinging nettle root extract (600 mg per day, 5:1 extract for 9 weeks), showed considerable reduction in SHBG (p<0.0005) and considerable improvement in urine volume and maximum urinary flow rate.

In a multicenter, double-blind clinical trial, 543 patients with early stages of BPH were administered a combination of extract of saw palmetto fruit (Serenoa repens) and stinging nettle root or finasteride (5α-reductase inhibitor). After 24 weeks, the mean maximum urinary flow rate (Qmax) increased 1.9 ml/s in the group administered extract of saw palmetto fruit and stinging nettle root and 2.4 ml/s in the finasteride group and no statistically significant difference was observed between the two groups (p=0.52). The researchers came to the conclusion that the efficacy of the combination of extract of saw palmetto fruit and stinging nettle root equals that of finasteride and is not associated with the size of the prostate. Nonetheless, better tolerance was observed with the combination of extract of saw palmetto fruit and stinging nettle root compared to finasteride.

Take 1 tablet, 3 times per day after meal with sufficient liquids. With the commencement of the treatment, improvement is gradually observed. Due to the chronic nature of BPH, the medication needs to be taken over an extended course of time.

Dosage form

Film-Coated Tablet


150 mg F.C tablets in container of 30

Patient information leaflet inside


  • Dried extract of root of stinging nettle (Urtica dioica)

Active Ingredients

  • polysaccharides
  • phytosterols
  • flavonoids
  • triterpenic acids

Contraindications and Cautions

Pregnancy and lactation: Due to other indications of stinging nettle, including its analgesic effects, products that contain it should be avoided during pregnancy. Also, it is best not to take large doses of such products during lactation.


Adverse Effects

With the recommended dosage, no adverse reaction has been reported. Mild digestive complaints might seldom occur. Sometimes decrease in urine production and seldom edema has been reported.


Drug Interaction

  1. Excessive use of Urtidin along with antidiabetic drugs and drugs that affect blood pressure can cause drug interactions.
  2. Urtidin intensifies the effects of central nervous system depressants.
  3. Iron supplements should be taken 1-2 hours after Urtidin.


Administration during Pregnancy and Lactation

Not to be taken during pregnancy. Avoid large doses during lactation.


Further Notes

  • Keep Urtidin F.C Tablet, like all other medication, away from sight and reach of children.
  • Avoid chewing Urtidin F.C Tablet.
  • Keep the medicine away from light and in temperatures below 25°C.
  • Keep this leaflet; you may need to read it again.

Based on presence of 22 mg amino acid based on alanine in each F.C tablet.